Wonder Electricals sets up 128 KW solar power plant

Wonder Electricals sets up 128 KW solar power plant


Wonder Electricals has taken a significant step towards sustainable and green energy by investing in a 128 kilowatt solar power plant.

The solar power plant is situated at Hyderabad Factory located at Plot No. 4, Industrial Park Kucharam Village, Manoharabad Mandal, Medak, Hyderabad, Telangana- 502336 and has become operational
now. In a strategic move to harness sustainable energy sources and mitigate electricity costs incurred during the production process.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 09 2024 | 7:05 PM IST



Source link

Sebi modifies foreign venture investors' registration, eligibility criteria


SEBI

FVCIs are required to hold their investments in demat form. | Photo: Shutterstock


Capital markets watchdog Sebi has notified rules to streamline the framework for the registration of Foreign Venture Capital Investors (FVCIs).


Under this, the process of granting registration to FVCIs and processing other post-registration references has been delegated to designated depository participants (DDPs) in line with provisions prescribed for FPIs (Foreign Portfolio Investors).


An applicant seeking registration as an FVCI is required to engage a DDP to avail of its services for obtaining a registration certificate as FVCI and at all times the DDP and the custodian of the FVCI shall be the same entity.

 


At present, the processing of applications for granting registration to FVCIs and related due diligence is carried out by the Securities and Exchange Board of India (Sebi).


“No person shall buy, sell or otherwise deal in securities as a foreign venture capital investor unless it has obtained a certificate granted by a designated depository participant on behalf of the Board (Sebi),” the regulator said in a notification issued on September 6.


FVCIs under the current rules are required to appoint a domestic custodian to monitor investment of FVCIs in India, furnish periodic reports and other information to Sebi.


Going by the notification, “a foreign venture capital investor or a global custodian acting on behalf of the foreign venture capital investor shall enter into an agreement with a designated depository participant and a custodian, before making any investment under these regulations”.


In addition, the regulator has made additions to the eligibility criteria for FVCI whereby Resident Indians (RIs)/ Non Resident Indians (NRIs)/ Overseas Citizen of India (OCI) can be constituent of the applicant. This is subject to conditions, such as contribution of a single NRI/ OCI/ RI should be below 25 per cent of the total contribution in the corpus of the applicant; the aggregate contribution by them should be below 50 per cent of the total contribution in the corpus of the applicant; and they should not be in control of the applicant.


At present, an investment company, investment trust, pension fund, investment partnership, mutual fund, endowment fund, charitable institution, university fund or any other entity incorporated outside India; an asset management company, investment management company, investment manager or any other investment vehicle incorporated outside India, could apply for registration as an FVCI.


Also, FVCIs are required to hold their investments in demat form. To give this effect, Sebi has amended Foreign Venture Capital Investors rules that will come into force with effect from January 1, 2025.


FVCI is an investor incorporated and established outside India, who invests primarily in unlisted securities of Venture Capital Undertakings and Venture Capital Funds. As of March, 2023, a total of 269 FVCIs are registered with Sebi. Further, the cumulative investments made by FVCIs directly in investee companies stood at Rs 48,286 crore during the period.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Sep 09 2024 | 6:34 PM IST



Source link

Tolins Tyres IPO subscribed 1.80 times


The offer received bids for 1.34 crore shares as against 74.88 lakh shares on offer.

The initial public offer (IPO) of Tolins Tyres received 1, 34, 50,866 bids for shares as against 74, 88,372 shares on offer, according to stock exchange data at 17:00 IST on Monday (9 September 2024). The issue was subscribed 1.80 times.

The issue opened for bidding on Monday (9 September 2024) and it will close on Wednesday (11 September 2024). The price band of the IPO was fixed between Rs 215 to 226 per share. An investor can bid for a minimum of 66 equity shares and in multiples thereof.

 

The IPO comprises a fresh issue of equity shares worth up to Rs 200 crore and an offer for sale (OFS) totaling Rs 30 crore by existing shareholders Dr. Kalamparambil Varkey Tolin and Jerin Tolin.

The objectives of the fresh issue include Rs 69.96 crore to be used for repayment and/or prepayment of certain outstanding loans, Rs 75 crore for augmenting long-term working capital requirements, Rs 23.15 crore for investment in wholly owned subsidiary Tolin Rubbers, and for general corporate purposes.

Promoters Dr Kalamparambil Varkey Tolin and Jerin Tolin and the promoter group holds an aggregate of 2, 84, 00,899 equity shares, aggregating to 92.64% of the pre-offer issued and paid-up equity share capital. Their post- IPO shareholding is expected to be around 68.53%.

Ahead of the IPO, Tolins Tyres on Friday, 6 September 2024, raised Rs 68.99 crore from anchor investors. The board allotted 30.53 lakh shares at Rs 226 each to 8 anchor investors.

Tolins Tyres is a tyre manufacturer of bias tyres used in a comprehensive range of vehicles, including light commercial, agricultural, and two- and three-wheeler vehicles as well as precured tread rubber. Ancillary products include bonding gum, vulcanizing solutions, tyre flaps, and tubes.

The business is divided into two main verticals: new tyre manufacturing and tread rubber production. Tyre retreading solutions are offered in India and exported to 40 countries, including the Middle East, East Africa, Jordan, Kenya, and Egypt. Exports contributed 5.38% to consolidated revenue, while the domestic market accounted for 94.62% in FY 2024.

The firm reported a consolidated net profit of Rs 26.01 crore and Sale of Rs 227.22 crore for the twelve months ended on 31 March 2024.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 09 2024 | 5:22 PM IST



Source link

Alok Ferro Alloys becomes wholly owned subsidiary company of Godawari Power & Ispat


Godawari Power & Ispat (GPIL) announced that its subsidiary, Alok Ferro Alloys (AFAL) made a buyback Offer for purchase of 29,91,875 equity shares.

The company being a holding Company did not participate in
the aforesaid buyback offer as result, the equity shares held by all other existing shareholders of AFAL have been purchased. Consequently. AFAL has become 100% Subsidiary Company of GPIL.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 09 2024 | 4:07 PM IST



Source link

Panacea Biotec freezes in 10% upper circuit; stock zooms 101% in 1 month


Shares of Panacea Biotec were locked in upper circuit of 10 per cent at Rs 270.60 on the BSE in Monday’s intra-day trade amid heavy volumes in an otherwise weak broader market. In the past one month, the stock of the smallcap pharmaceutical company has zoomed 101 per cent, from the levels of Rs 134.55. 

At 02:49 PM, the BSE Sensex was up 0.35 per cent, as compared to the 0.5 per cent decline in the BSE MidCap and 0.87 per cent fall in the BSE Smallcap index. The average trading volumes on the counter had jumped nearly three-fold. A combined 2.1 million equity shares of the company had changed hands and there are pending buy orders for nearly 100,000 shares on the NSE and BSE.

On August 14, the Indian Council of Medical Research (ICMR) and Panacea Biotec announced the start of the first ever Phase III clinical trial for a dengue vaccine in India. DengiALL is a tetravalent recombinant live attenuated tetravalent candidate vaccine that targets all the four serotypes of Dengue that are prevalent across the world.

 


Dengue is a major public health concern in India, with the country ranking among the top 30 countries with the highest incidence of the disease.


Panacea Biotec, in its FY24 annual report, had said that the company is committed towards growth of the Indian private market vaccine franchise with additional launches scheduled in the next 18 to 24 months and hopes to introduce NucoVac11 and DengiAll among other products to meet unmet medical needs in 2026, subject to successful completion of the Phase III clinical trials and receipt of requisite regulatory approvals. EasySix (the world’s first fully liquid wP-based Hexavalent vaccine) continues to be the market leader.


Panacea Biotec is one of the leading manufacturers of paediatric vaccines and has played a pivotal role in the eradication of Poliomyelitis (Polio) from India and many other countries. Panacea Biotec had been one of the largest suppliers of oral polio vaccines to UNICEF, the Government of India and other developing countries. 


Over more than the past two decades, the company has supplied more than 10 billion doses of polio vaccine in India and developing countries and enabled more than 190 million immunisations by supplying fully liquid wP based combination vaccines.


The Indian vaccine industry has seen a significant increase in demand for vaccines, especially after the sudden outbreak of Covid-19. The government’s continued efforts and awareness programs to promote the usage of vaccines has resulted in the public becoming more aware, comfortable and familiar with vaccinations. All this is expected to add to the market growth of the company in future.

The Indian vaccine market is estimated at around Rs 290 billion (approximately $3.5 billion) in 2023. The market is further expected to reach around Rs 996 billion (approximately $12 billion) by 2030, growing at a compound annual growth rate (CAGR) of around 10-12 per cent in the near future.

The future growth in the Indian vaccine industry will be driven by several factors like government initiatives, population growth, advancements in vaccine technology, government-led immunisation programs, investment support in research and development (R&D) by government funding agencies, increased awareness and access and income levels allowing people to vaccinate their families against deadly diseases, the company said in its FY24 annual report.

First Published: Sep 09 2024 | 3:28 PM IST



Source link

Metal shares fall


Metal stocks were trading in the negative zone, with the BSE Metal index falling 377.72 points or 1.21% at 30945.6 at 13:42 IST.

Among the components of the BSE Metal index, NMDC Ltd (down 2.32%), National Aluminium Company Ltd (down 2.07%),Hindalco Industries Ltd (down 1.9%),Steel Authority of India Ltd (down 1.86%),Coal India Ltd (down 1.67%), were the top losers. Among the other losers were Tata Steel Ltd (down 1.45%), Jindal Stainless Ltd (down 1.27%), Vedanta Ltd (down 0.74%), Jindal Steel & Power Ltd (down 0.55%), and JSW Steel Ltd (down 0.34%).

On the other hand, APL Apollo Tubes Ltd (up 0.13%), moved up.

 

At 13:42 IST, the BSE SmallCap was down 522.77 or 0.93% at 55455.09.

The BSE 150 MidCap Index index was down 71.13 points or 0.43% at 16513.35.

The Nifty 50 index was up 56.85 points or 0.23% at 24909.

The BSE Sensex index was up 295.07 points or 0.36% at 81479.

On BSE,1477 shares were trading in green, 2492 were trading in red and 151 were unchanged.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 09 2024 | 2:00 PM IST



Source link

YouTube
Instagram
WhatsApp